comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 01:39:21 - browse：861

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Sanofi seeks simpler, safer CRISPR sickle cell cure

explore

WSS

Flu vaccine reformulation won't be easy, manufacturers warn

In early work, researchers turn to CRISPR to treat Alzheimer's

How dance can help nurses traumatized by Covid

Group opposing PBM reform sets lobbying record

Sanders adds drug shortage policies to pandemic preparedness bill

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Pumping milk in bathrooms at health conferences is common

What does generative AI mean for health care? We asked experts

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Apple is now the first public company to be valued at $3 trillion

HPV vaccine, cervical cancer study delivers historic results

Affirmative action in medical school literally saved lives

Google and Epic fight stronger regulation of AI in health care

focus

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Google and Epic fight stronger regulation of AI in health care

Pumping milk in bathrooms at health conferences is common

Immunocompromised patients offer clues on chronic Covid

Doctors find melanoma drugs effective against rare brain cancer

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

entertainment

explore

knowledge

focus